Immunohistochemical (IHC) analysis using a commercial ovarian cancer tissue array (OV481) was subsequently performed to confirm the BCL2A1 expression pattern in clinical ovarian cancer specimens. This evidence concerns the gene BCL2A1 and ovarian carcinoma.